APLIF
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes Favipiravir for pandemic influenza and COVID-19; ATI-2307, an antifungal candidate, which is in clinical stage for the treatment of cryptococcal meningitis and invasive candidiasis; ATI-1503 that develops a class of gram-negative targeting antibiotics; ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. The company has a strategic alliance with AiPharma Global Holdings LLC for the development of Avigan/Reeqonus (favipiravir). Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q3 | -0.01 | $114,887 | -$292,830 |
| 2025 Q2 | -0.01 | $103,935 | -$759,376 |
| 2025 Q1 | -0.01 | $0 | -$6,356 |
| 2025 Q4 | 0.00 | -$12,606 | $1M |
| 2024 Q3 | -0.00 | $108,359 | -$443,073 |
| 2024 Q2 | -0.01 | $4,690 | $407,369 |
| 2024 Q1 | -0.01 | $0 | -$132,075 |
| 2024 Q4 | -0.01 | $11,697 | -$473,727 |